Compare FedEx Corporation (FDX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Spyre Therapeutics Inc. Common Stock — how do they compare? FedEx Corporation trades at $291.77 (market cap $68.77B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: FedEx Corporation is far larger — about 9.1× Spyre Therapeutics Inc. Common Stock's market cap, and FedEx Corporation pays a 1.68% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FedEx Corporation for 87 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FDX | SYRE | |
|---|---|---|
Market Cap | $68.77B | $7.52B |
Volume | 914,308 | 1,441,031 |
Sector | Industrials | Health |
52-Week High | $339.35 | $108.92 |
52-Week Low | $189.87 | $22.18 |
Typical Hold Time | 87 Days | 0 Days |
Enterprise Value | $98.41B | $6.52B |
Dividend Yield | 1.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $291.28, down 0.33% on the day, with a bearish technical signal. The stock shows solid fundamentals with a P/E of 15.67 and net income margin of 4.68%, though revenue has been flat recently. Recent news includes a $300 million electric truck order and shareholder approval of executive pay. Cash flow is projected to improve significantly in 2026.
The outlook is mixed: strong analyst buy consensus (57%) and a $307.55 price target suggest upside, but technical indicators and rising fuel costs pose near-term risks. Long-term growth depends on execution of cost cuts and capitalizing on industry tailwinds.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
